Curtiss-Wright (CW) Q1 2026 Earnings Transcript

Curtiss-Wright posted strong Q1 results with sales up 13% to $914 million, operating margin expanding 100 bps to 17.6%, and diluted EPS rising 23%, while new orders increased 15% and backlog hit a record nearly $4.3 billion. Management raised 2026 guidance across sales (7%-8%), operating margin (19.0%-19.2%), EPS ($14.90-$15.30), and free cash flow ($580 million-$600 million), citing broad-based strength in defense, commercial nuclear, and aerospace. The call also highlighted improving SMR momentum, durable Navy demand, and continued M&A capacity, reinforcing a constructive outlook.

Analysis

CW is signaling that the real story is not just end-demand but conversion of backlog into pricing power. The combination of a 1.3x book-to-bill, record backlog, and margin expansion across all segments means this is now a self-funding compounding machine: higher throughput is funding more R&D and capacity, which then supports more sole-source content on harder programs. That creates a flywheel, but it also raises the bar for execution because the stock is increasingly priced on sustained conversion rather than simply on order growth.

The second-order winner is the broader defense/nuclear supply chain that can actually deliver under tighter schedules. CW’s emphasis on second-sourcing, semis, rare earths, and domestic production capacity implies incumbents with brittle supply chains may lose share even in a strong budget environment, while niche suppliers with qualification breadth benefit. The flip side is that commercial nuclear is becoming a bigger mix item, which likely compresses volatility in the long run but raises project-timing risk in the near term, especially around AP1000 and SMR revenue recognition.

The market may be underestimating how much of the current narrative is a multi-year capacity build rather than a one-quarter beat. If order momentum in naval and defense electronics persists into Q2/Q3, the company can keep re-rating on backlog visibility; if not, the main risk is that investors are paying for a 2027-2028 secular inflection that could be delayed by procurement timing or program slippage. The key tell over the next 1-2 quarters is whether defense electronics and commercial nuclear can maintain order strength without relying on one-off timing catch-ups.

Key Decisions for Investors

• Long CW on pullbacks over the next 2-4 weeks; thesis is backlog-supported EPS compounding with 12-18 month visibility, but size modestly because the valuation now embeds continued execution.
• Pair trade: long CW / short a lower-quality defense supplier with weaker backlog conversion and less pricing power; the cleaner balance sheet and higher FCF conversion should keep CW outperforming over 6-12 months.
• Buy CW Jan-2027 call spreads to express the 2027 commercial nuclear and naval capacity-expansion upside; upside is meaningful if SMR and AP1000 orders convert, while defined risk limits timing slippage.
• Avoid chasing pure-play industrial cyclicals exposed to weak general industrial end markets; CW’s defense/nuclear mix is the better risk-adjusted exposure for the next 2-3 quarters.
• Watch for a tactical hedge via short-term puts if AP1000 or SMR timing slips, because the stock could de-rate quickly if investors start doubting the 2026-2027 order conversion ramp.